- Home
- NCTY vs ATOS Comparison
NCTY vs ATOS Comparison
Compare NCTY & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCTY
- ATOS
- Stock Information
- Founded
- NCTY 1999
- ATOS 2009
- Country
- NCTY China
- ATOS United States
- Employees
- NCTY N/A
- ATOS N/A
- Industry
- NCTY Business Services
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- NCTY Consumer Discretionary
- ATOS Health Care
- Exchange
- NCTY Nasdaq
- ATOS Nasdaq
- Market Cap
- NCTY 98.0M
- ATOS 96.8M
- IPO Year
- NCTY 2004
- ATOS 2012
- Fundamental
- Price
- NCTY $10.20
- ATOS $0.62
- Analyst Decision
- NCTY
- ATOS Strong Buy
- Analyst Count
- NCTY 0
- ATOS 3
- Target Price
- NCTY N/A
- ATOS $7.00
- AVG Volume (30 Days)
- NCTY 105.3K
- ATOS 699.0K
- Earning Date
- NCTY 01-01-0001
- ATOS 05-12-2025
- Dividend Yield
- NCTY N/A
- ATOS N/A
- EPS Growth
- NCTY N/A
- ATOS N/A
- EPS
- NCTY 9.91
- ATOS N/A
- Revenue
- NCTY $24,286,983.00
- ATOS N/A
- Revenue This Year
- NCTY N/A
- ATOS N/A
- Revenue Next Year
- NCTY N/A
- ATOS N/A
- P/E Ratio
- NCTY $2.26
- ATOS N/A
- Revenue Growth
- NCTY 2.82
- ATOS N/A
- 52 Week Low
- NCTY $5.63
- ATOS $0.55
- 52 Week High
- NCTY $20.59
- ATOS $1.81
- Technical
- Relative Strength Index (RSI)
- NCTY 38.89
- ATOS 42.51
- Support Level
- NCTY $9.71
- ATOS $0.56
- Resistance Level
- NCTY $12.27
- ATOS $0.67
- Average True Range (ATR)
- NCTY 1.27
- ATOS 0.06
- MACD
- NCTY -0.23
- ATOS 0.00
- Stochastic Oscillator
- NCTY 7.81
- ATOS 43.75
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China and other areas.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.